Core Viewpoint - Hongyuan Pharmaceutical (301246) confirmed on November 7 that its lithium hexafluorophosphate and sodium hexafluorophosphate products are key materials for electrolytes, with downstream customers being electrolyte manufacturers [1] Group 1 - The company produces lithium hexafluorophosphate and sodium hexafluorophosphate [1] - These products are essential components in the production of electrolytes [1] - The company's downstream clients are primarily electrolyte manufacturers [1]

格隆汇11月7日丨宏源药业(301246.SZ)在互动平台表示，公司目前没有新型含氟聚醚电解质技术的研 发。 ...

Core Viewpoint - The company has made progress in the development of solid-state batteries, specifically in the preparation of kilogram-level sulfide electrolyte precursors and electrolyte samples [2] Group 1 - The company has completed the preparation of kilogram-level sulfide electrolyte precursors and electrolyte samples [2] - The company is currently conducting testing and optimization work on the solid-state electrolyte [2] - Investors are encouraged to follow the company's information disclosure for more specific updates [2]

Group 1 - The company emphasizes the importance of developing its lithium hexafluorophosphate business [1] - The company plans to enhance its competitiveness in the lithium hexafluorophosphate sector through technological upgrades and extending upstream in the supply chain [1]

Core Viewpoint - Hongyuan Pharmaceutical's lithium hexafluorophosphate products are applicable in the fields of new energy vehicles, energy storage, and consumer electronics [2] Group 1 - The company responded to investor inquiries on October 31 regarding the applications of its lithium hexafluorophosphate products [2]

Core Viewpoint - Hongyuan Pharmaceutical reported that the production and sales of lithium hexafluorophosphate and sodium hexafluorophosphate are currently operating normally, with full production and sales capacity [2] Group 1 - The company confirmed that its lithium hexafluorophosphate product is in full production and sales [2] - The company also stated that its sodium hexafluorophosphate product is experiencing the same operational status [2]

Core Viewpoint - Hongyuan Pharmaceutical's Dapagliflozin Tablets have passed the consistency evaluation, indicating a significant milestone for the company in the pharmaceutical industry [2] Company Summary - Hongyuan Pharmaceutical announced on October 31 that its Dapagliflozin Tablets have successfully passed the consistency evaluation, which is a crucial step for the product's market competitiveness [2]

Group 1 - The company, Hongyuan Pharmaceutical, stated on October 31 that it currently has no new research and development projects for influenza-related products [2]

Core Viewpoint - Hongyuan Pharmaceutical's products, Pudilan Anti-inflammatory Tablets and Qingre Jiedu Oral Liquid, are effective in anti-inflammatory and antiviral treatments [2] Group 1 - The company responded to investor inquiries on October 31 regarding the efficacy of its products [2] - Pudilan Anti-inflammatory Tablets and Qingre Jiedu Oral Liquid are highlighted for their anti-inflammatory and antiviral properties [2] - The company advises that medication should be taken according to medical advice or consultation with a licensed physician [2]

Core Viewpoint - Hongyuan Pharmaceutical, established in 2002 and listed on the Shenzhen Stock Exchange in March 2023, operates in the pharmaceutical and lithium battery materials sectors, showcasing a full industry chain advantage [1] Group 1: Business Performance - For Q3 2025, Hongyuan Pharmaceutical reported revenue of 1.317 billion yuan, ranking 14th out of 47 in the industry, with the top competitor, Pro Pharmaceutical, generating 7.764 billion yuan [2] - The main business composition includes raw materials and pharmaceutical intermediates at 468 million yuan (56.14%), lithium battery materials at 239 million yuan (28.65%), and organic chemical raw materials at 112 million yuan (13.42%) [2] - The net profit for the same period was -1.944 million yuan, placing the company 40th in the industry, with the leading company, Zhejiang Pharmaceutical, achieving 867 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Hongyuan Pharmaceutical's debt-to-asset ratio was 26.53%, slightly up from 25.78% year-on-year, which is below the industry average of 27.75% [3] - The gross profit margin for the period was 12.71%, an increase from 12.54% year-on-year, but still below the industry average of 35.38% [3] Group 3: Executive Compensation - The chairman, Yin Guoping, received a salary of 626,800 yuan in 2024, a decrease of 24,300 yuan from 2023 [4] - The general manager, Xu Shuangxi, earned 491,600 yuan in 2024, down by 24,600 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 9.76% to 28,000, while the average number of circulating A-shares held per account increased by 8.78% to 5,608.43 [5] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked as the eighth largest, holding 1.1009 million shares, a reduction of 201,300 shares from the previous period [5]